Health Canada Priority Review targets an expedited 180-day review period for givinostat, reflecting Italfarmaco’s commitment to Canadian DMD ...

The companies anticipate finalising the acquisition in the third quarter of 2026.

Biotech firm Edgewise Therapeutics said on Monday it would sell its experimental muscular dystrophy drug and related business ...

In addition to the upfront fee, Servier has committed up to $1.1 billion in regulatory and commercial milestones to acquire ...

The brothers shared an unbreakable bond while living with Duchenne muscular dystrophy, a rare genetic disorder that causes ...

Under the agreement, Servier will pay $1.55 billion upfront, with up to an additional $1.1 billion tied to regulatory and ...

Explore how researchers are using next-generation CRISPR therapies to target the root cause of muscle degeneration.

For Duchenne and Becker muscular dystrophies, muscle biopsy may show whether dystrophin, a muscle protein, is missing or abnormal, and DNA testing is used to analyze the condition of the related gene.

The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion ...

The muscular dystrophies represent disorders of progressive muscular degeneration and weakness. As a group, they exhibit clinical heterogeneity that reflects diverse molecular mechanisms responsible ...

Orphan Drug Designation (ODD) recognizes Duchenne muscular dystrophy as a rare disease with significant unmet medical need without an established ...

University of Maine researchers have published new findings about how muscles form, why certain muscle diseases develop and ...